INTRODUCTION
Ulcerative colitis affects ϳ0.2% of the population and is characterized by chronic inflammation of the colonic mucosa leading to a depletion of the goblet cells, disruption of crypt morphology, ulceration, and an increased risk of carcinoma. The etiology of the disease is unclear, but it is likely that pathogenesis is dependent on the interaction between local immune reactions and environmental factors in genetically susceptible individuals [1] . Macrophages contribute to pathogenesis, with large numbers infiltrating into the mucosa and providing a major source of inflammatory mediators such as TNF-␣ and oxygen radicals [2, 3] . Solute carrier family 11a member 1 [Slc11a1; formerly natural resistance-associated macrophage protein 1 (Nramp1)] is a macrophage [4, 5] -and dendritic cell (DC) [6] -expressed proton/divalent cation transporter, which was described originally for its roles in regulating resistance and susceptibility to Salmonella typhimurium, Leishmania donovani, and Mycobacterium bovis bacillus Calmette-Guerin in mice (reviewed in refs. [7, 8] ). During the activation of macrophages, Slc11a1 has been shown to exert a range of pleiotropic effects (reviewed in refs. [9 -11] ), including the induction of proinflammatory cytokines such as TNF-␣ [12] , the up-regulation of MHC class II expression and antigen presentation [6, 13] , and release of reactive oxygen and nitrogen intermediates [14] . It therefore seems plausible that Slc11a1 could contribute to the pathogenesis of ulcerative colitis. This is supported by human genetic studies showing allelic associations with ulcerative colitis in Japan [15] and South Africa [16] . Although an association between polymorphism at SLC11A1 and ulcerative colitis had not been observed earlier in The Netherlands [17] , all of the human studies undertaken to date have used small sample sizes, precluding any conclusion as to whether this represents ethnic differences or is simply a factor of underpowered studies. Analysis of ulcerative colitis in a mouse model could provide more defin-itive evidence for a role for Slc11a1 in ulcerative colitis, providing valuable information about the molecular pathways of disease pathogenesis.
Although no murine model provides a perfect correlate of human disease, many studies (e.g., refs. [18 -20] ) undertaken since the 1990s have used chemical induction of ulcerative colitis by administration of 3-10% dextran sulfate sodium (DSS) in the drinking water as a murine model for ulcerative colitis. During the first cycle of DSS administration, animals develop an acute colitis resembling ulcerative colitis, characterized by mucosal inflammation of the colon, with ulceration, loss of body weight, and bloody diarrhea. By adapting this to a low-dose, 2% DSS model, we now demonstrate clear phenotypic differences in Slc11a1 wild-type (wt) and congenic Slc11a1 mutant (mt) mice during acute and chronic stages of ulcerative colitis. We show that acute colitis is enhanced in Slc11a1 wt mice and is accompanied by differences in gross pathology, infiltration of monocytes/macrophages into the colon, and T cell-derived IFN-␥ and IL-10 in lymph nodes (LN) and spleen and in induction of the Th17-inducing, proinflammatory, acute-phase protein IL-6 but not the Th1-inducing cytokine IL-12 locally in the colon.
MATERIALS AND METHODS

Mice
Congenic N20 B10.L-Lsh (ϭNramp1; ϭSlc11a1) were bred in-house [21] following 20 generations of backcrossing the Slc11a1 wt allele from C57L mice onto a C57BL/10ScSn (ϭB10) background that carries a natural, nonfunctional mt allele at Slc11a1 that is equivalent in loss-of-function to gene-disrupted mice [22] . These N20 mice (referred to hereafter as Slc11a1 wt) are congenic with Slc11a1 mt B10 mice (referred to hereafter as Slc11a1 mt), except for the ϳ10-Mb interval distal to D1Mit80 and proximal to D1Mit44 on chromosome 1 that carries the Slc11a1 gene. All breeding and procedures were carried out under license and UK Government Home Office regulations. Male mice between 8 and 12 weeks old were used, age-matched Ϯ 2 weeks within each experiment as indicated for each experiment.
DSS-induced colitis
Acute colitis was induced by administration of 1 ϫ 7 day cycle of 2%, 3%, or 5% DSS (MW, 40,000; ICN Biochemicals Inc., Aurora, OH, USA) in the drinking water, and body weight was monitored daily. Control mice were given drinking water only. Groups of nine to 12 mice/strain were used to monitor acute colitis. In some experiments, groups of three to four mice were killed at intervals through the 7-day cycle, and colon lengths, spleen weights, and body weights were recorded. Body weight change for each individual mouse was calculated as follows: Percent weight change ϭ [(weight at specific day-weight on Day 0)/weight on Day 0)ϫ100]. Chronic colitis was induced by 2 ϫ 7 day cycles of administration of 2% DSS in the drinking water, with a 7-day recovery period between cycles to monitor the survival rate of these mice for 26 days. Groups of nine to 15 mice/strain were used for survival experiments.
Tissue preparation for histology and scoring of colon pathology
Mice were killed by cervical dislocation, and colons were harvested from mice treated with 0% or 2% DSS in the drinking water for 7 days. Tissues were washed thoroughly in PBS and fixed in 4% formalin and embedded in paraffin. Sections of 5 M were stained with H&E using standard procedures. Immunohistochemistry was performed on fixed sections using affinity-purified rat anti-mouse F4/80 mAb IgG2a, (clone BM8; eBioscience, UK) with biotinylated rabbit anti-rat IgG as the secondary antibody (Vector Laboratories, Burlingame, CA, USA). F4/80 antigen was visualized using the ABC/DAB system (Vector Laboratories), and sections were counterstained with hematoxylin. Matched isotype antibody was used as a negative control. Disease severity was measured on the basis of a histopathological score in the H&E-stained, sectioned intestinal tissue as described by others [23] . Briefly, the colon sections were scored 0 -4, based on the level of pathology: 0, normal tissues; 1, mild inflammation in the mucosa with some infiltrating mononuclear cells; 2, increased level of inflammation in the mucosa with more infiltrating cells, crypt glands have pulled away from the basement menbrance, mucin depletion from goblet cells, and the epithelium begins to pull away from the mucosa into the lumen; 3, extensive infiltrating cells in the mucosa and submucosa area, crypt abscesses present with increased mucin depletion, and epithelial cell disruption; and 4, massive infiltrating cells in the tissue, complete loss of crypt. Sections were analyzed by light microscopy at 200ϫ magnification, with the scorer blind to the experimental group. Four fields from different sections of each colon tissue were examined for each mouse; the average score was calculated as the histology score for that mouse. Control groups: n ϭ 2 per strain; 2% DSS-treated groups: n ϭ 7 per strain.
Flow cytometry of infiltrating leukocytes
Complete colons harvested from mice treated with 2% DSS in drinking water for 7 days were opened longitudinally and washed thoroughly in PBS buffer. Colons were chopped and digested with DNase and collagenase A in RPMI 1640 (Invitrogen, Paisley, UK) containing 10% FBS (Invitrogen) and 100 U/ml penicillin/100 g/ml streptomycin (Invitrogen). Cells were filtered through a 70-m sieve (BD PharMingen, San Diego, CA, USA). Single-cell suspensions were stained for one-half hour with the following antibodies (all antibodies are BD PharMingen unless stated): anti-CD45 (leukocyte cell marker, clone 30-F11), anti-CD4 (CD4 T cell marker, clone RM4-5), anti-CD8 (CD8 T cell marker, clone 53-6.7), anti-CD11b to detect complement receptor 3 on fresh monocytes (clone M1/70), or anti-F4/80 as a pan-macrophage marker (clone BM8, eBioscience). Cells were washed in PBS and analyzed by flow cytometry using FACSCalibur (BD PharMingen).
Cytokine profiles in spleen and draining LN
Mesenteric LN and spleens were harvested from mice after 7 days of treatment with 2% DSS in the drinking water. Cell suspensions were prepared in RPMI 1640 containing 10% FBS and 100 U/ml penicillin/100 g/ml streptomycin and plated at 4 ϫ 10 6 cells/well in 24-well plates and stimulated with or without plate-bound anti-CD3 (clone 145-2C11, BD PharMingen) and soluble anti-CD28 (clone 37.51, BD PharMingen) antibodies. Supernatants were collected after 72 h, and IL-10 and IFN-␥ levels were measured by sandwich ELISA using OptEIA kits from BD PharMingen.
RNase protection assays
RNA was prepared from colons harvested from Slc11a1 wt and congenic Slc11a1 mt mice at Days 0, 3, and 7 of treatment with 2% DSS in the drinking water. Colons were washed in PBS, snap-frozen in RNase-free tubes, mixed with TRIzol (Invitrogen), and homogenized using a power homogenizer. RNA was extracted with chloroform, precipitated with isopropyl alcohol, washed in 75% ethanol, and dissolved in RNase-free water. The RNA was purified further using RNeasy MinElute cleanup kits (Qiagen, Crawley, UK), according to the manufacturer's instructions, and its quality and concentration were assessed using an Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNase protection assays were conducted using 32 P radio-labeled probes according to the manufacturers' instructions. All assay components were supplied as part of the Ribonuclease Protection Assay kit (BD Biosciences, San Diego, CA, USA), except the ␣ 32 P-labeled UTP (Perkin Elmer, Wellesley, MA, USA). Briefly, antisense RNA probes were synthesized from DNA templates of distinct lengths, each representing a sequence from a distinct mRNA species of interest, using a T7 DNA-dependent RNA polymerase and nucleotide pool containing 32 P-labeled UTP. RNA probes were hybridized in excess with purified RNA from colon samples overnight followed by an RNase A and T1 digestion of nonhybridized probe. Protected, double-stranded RNAs were then resolved on a denaturing polyacrylamide gel. The probe template set used was the mouse cytokine template kit mCK-2b containing the following cytokine genes that we could detect accurately on colonic RNA: IL-12p35, IL-12p40, IL-10, IL-1␣, IL-18, IL-6, IFN-␥, and migration inhibition factor (MIF), along with alternative control genes L32 and GAPDH. Autoradiographs were pre-pared from radiolabeled gels with signal quantification preformed using AlphaImager (Alpha Innotech, GRI, UK). Data (meanϩSE) for three mice/group/ time-point were expressed as specific cytokine gene over the GAPDH control.
Statistics
All phenotypes were determined blind to the experimental group. Unpaired, two-tailed Student's t-tests were used to compare differences between mouse strains. Differences between experimental groups were considered significant for P values Ͻ0.05.
RESULTS
Establishment of a colitis phenotype in B10 background Slc11a1 congenic mice
Preliminary experiments using the published [18 -20] protocol and administering 5% DSS in the drinking water resulted in 25-30% weight loss over 5-7 days in Slc11a1 wt and congenic Slc11a1 mt mice, and 80 -100% mice died between Days 5 and 7 (data not shown). In subsequent experiments, we reduced the dose to 2% DSS in the drinking water. Administration of 2% DSS provided the clearest phenotypic difference between Slc11a1 wt and congenic Slc11a1 mt mice ( Fig. 1) , resulting in 8 -14% body weight loss in one experiment (Fig. 1A ) and 15-25% body weight loss in a second (Fig. 1B) and reduced mortality (Ͻ20%; data not shown) in both experiments, where we observed significantly greater loss in body weight in Slc11a1 wt compared with their congenic Slc11a1 mt counterparts at Days 6 and 7 of 2% DSS treatment, providing a phenotypic window in which to study the associated pathology and immunological correlates of acute colitis. This phenotypic difference in the acute phase of colitis translated into a dramatic difference in survival rates between Slc11a1 wt and congenic Slc11a1 mt mice in the chronic colitis model (Fig.  2) , and 100% survival was observed for mt mice compared with only 25% survival of wt mice. In follow-up experiments, we focused on the acute colitis model (i.e., primary DSS administration over 7 days) to determine the innate, Slc11a1-mediated antecedents of the chronic colitis observed with the second cycle of DSS treatment.
Colonic pathology and histopathology are more severe in Slc11a1 wt mice
The decrease in body weight observed over 7 days of treatment with 2% DSS in the drinking water was accompanied by a decrease in colon length (Fig. 3A) and an increase in spleen: body weight ratio (Fig. 3B) in both mouse strains. At Days 5 and 7 of treatment, colon length in Slc11a1 wt mice was significantly smaller than in Slc11a1 mt mice (Fig. 3A) . At Day 7 of treatment, the spleen:body weight ratio of Slc11a1 wt mice was significantly greater than in Slc11a1 mt mice (Fig. 3B) . H&E-stained sections of colons harvested from mice at Day 7 of treatment (Fig. 4) confirmed the exacerbated disease observed in Slc11a1 wt mice compared with mt mice. Compared with the deep, even crypts observed in a section of normal colonic mucosa of untreated mice (Fig. 4, A and C) , colons from wt mice (Fig. 4G) showed heavy cellular infiltration, ulceration, and near-complete tissue destruction of the crypts. Colons from mt mice (Fig. 4E) show a less-severe phenotype with partially strangulated and depleted crypts and some ulcers developing. This is confirmed by the quantitative measurement using the histological scores (details described in Materials and Methods; Fig. 3C ).
Slc11a1 wt mice show enhanced monocyte/macrophage colonic infiltrates
To understand the cellular composition of the massive infiltrates observed in the colons of mice, flow cytometry was performed on single-cell suspensions prepared from colons harvested at Day 7 of 2% DSS treatment (Fig. 5) . No baseline differences between wt and mt mice were observed at Day 0 (Fig. 5A ). There was a trend for a larger number of CD45-positive cells in the infiltrate of wt mice compared with mt at Day 7 (Fig. 5B) . CD45 is the leukocyte common antigen present on all hematopoietic cells except mature red cells and their immediate progenitors. This difference in the number of CD45-positive cells reflects the contribution of a significantly higher infiltrate of CD11b and F4/80-positive monocyte/macrophages as a percentage of the total cellular composition in colon cell suspensions from Slc11a1 wt mice compared with Slc11a1 mt mice (Fig. 5B) . In sections stained immunohistochemically for the pan macrophage marker F4/80, few positive cells were present at Day 0 for mt (Fig. 4B) or wt (Fig. 4D) mice. At Day 7, F4/80-positive cells were observed in the submucosa and lamina propria in mt (Fig. 4 , F and F ZOOM ) and wt (Fig. 4, H and H ZOOM ) mice, with the much more extensive infiltrate and ulceration in the lamina propria of wt mice, making the major contribution to the increase in overall F4/ 80-positive cells observed in wt compared with mt mice (Fig.  5B) . Percentages of CD4-positive and CD8-positive T cells infiltrating the colon at Day 7 were equivalent in wt and mt mice (Fig. 5B) .
Draining LN and splenic cytokine responses
Changes in spleen:body weight ratios suggested immunological changes beyond the level of local responses in the colon by Day 7 of treatment with 2% DSS in the drinking water. To determine whether these changes reflected the local differences observed in the colons of Slc11a1 wt versus mt mice, cells were harvested from mesenteric, draining LN and spleens and stimulated in vitro with the nonspecific T cell-activating signals (anti-CD3 and anti-CD28). This demonstrated a clear, inverse relationship between IFN-␥ (Fig. 6A) and IL-10 ( Fig. 6B ) responses in Slc11a1 wt compared with mt mice, resulting in a significantly higher ratio of IFN-␥:IL-10 ( Fig. 6C ) in wt compared with mt mice in LN and splenic T cell responses. These differences in T cell responses, already apparent at Day 7 of primary treatment with DSS, are likely to be important antecedents of the dramatic differences observed in mortality in the repeat treatment chronic disease model (Fig. 2) .
Cytokine profiles in the colon using RNase protection assays
To gain further insight into the signals being generated in the colons of Slc11a1 wt compared with mt mice, RNA was prepared from colons harvested at Days 0, 3, 5, and 7 of 2% DSS treatment and a range of proinflammatory cytokines analyzed using an RNase protection assay. These results (Fig. 7) showed that despite the higher IFN-␥ T cell responses observed in LN and spleens, RNA levels for the Th1-inducing cytokine IL-12 did not differ significantly between Slc11a1 wt and mt mice at any of Days 0, 3, 5, or 7 ( Fig. 7) of DSS treatment. Interestingly, however, significantly higher levels of IFN-␥ mRNA were also observed locally in the colons of Fig. 3 . Mean ϩ SEM colon length (A) and spleen:body weight ratio (B) in Slc11a1 wt compared with congenic Slc11a1 mt mice followed over 7 days of treatment with 2% DSS in the drinking water. These data are from a third independent experiment compared with the two experiments shown in Figure  1 , A and B; n ϭ 4 -5 mice/group/time-point; *, P Ͻ 0.05. (C) Quantitative assessment of the H&E-stained histological sections (see Fig. 4 ) from the colon tissues of wt and mt mice after 7 days treatment with normal or 2% DSS water; n ϭ 2 for control mice; n ϭ 7 for DSS-treated mice. Fig. 2 . Survival rates of Slc11a1 wt and congenic Slc11a1 mt mice after two cycles of 2% DSS treatment. Groups of 12-15 mice were given 7 days of 2% DSS water, followed by 7 days of normal drinking water, and another circle of 7 days of DSS. Slc11a1 wt mice had up to 75% mortality, and all Slc11a1 mt mice survived. Similar results were observed in a replicate experiment.
Slc11a1 wt compared with mt mice at Day 7 of treatment ( Fig.  7) , accompanied by enhanced levels of the proinflammatory cytokine IL-6. Other differences between pro (IL-12p35, IL12p40, IL-1␣, IL-18)-or anti (IL-10)-inflammatory cytokine mRNA levels in the colon between wt and mt mice did not achieve statistical significance. No significant differences between wt and mt mice were observed for RNA preparations made from colons harvested at Days 0, 3, or 5.
DISCUSSION
A growing number of studies (reviewed in refs. [11, 24] ) now provide evidence that polymorphism at SLC11A1 is globally associated with autoimmune disease susceptibility in man, but few studies have attempted to relate this to the mechanism of action of the protein and its many pleiotropic effects on macrophage (reviewed in refs. [7, 8] ) and DC [6] function. In this study, we have adapted a model of chemically induced ulcerative colitis to examine Slc11a1-mediated events that occur during acute colitis. Previous studies of murine models have demonstrated the importance of the balance between proinflammatory IFN-␥ and anti-inflammatory IL-10 in pathogenesis of colitis (reviewed in refs. [25, 26] ). Our results concur in that Slc11a1 wt mice with enhanced, acute (i.e., following just one 7-day cycle of DSS treatment) ulcerative colitis show higher IFN-␥ and lower IL-10 following polyclonal CD4 T cell activation of cells from draining LN and splenic T cell responses, as well as higher levels of mRNA for IFN-␥ in the colon at Day 7 of treatment. These early differences in remote T cell activity in the spleen, already present 7 days after primary DSS treatment, are likely to be important antecedents of the dramatic differences in mortality between mt and wt mice that we observed after a second round of DSS treatment. Interestingly, the high level of IFN-␥ in the colon at Day 7 was not associated with enhanced induction of the Th1-inducing cytokine IL-12 but with higher levels of the proinflammatory acute-phase protein IL-6. This occurred at a time when Slc11a1 wt mice show an enhanced infiltrate of monocytes/macrophages, but not CD4 or CD8 T cells, into the colon compared with mt mice, suggesting that monocytes/macrophages may be the source of enhanced IL-6 mRNA. This could be secondary to an initial Slc11a1-regulated difference in activation of resident gut macrophages or DC. We cannot, therefore, conclude that different amounts of IL-6 mRNA were being produced directly by Slc11a1-expressing macrophages. Nevertheless, this is the first report of changes in IL-6 expression as a pleiotropic or downstream effect mediated by Slc11a1. In addition, no previous studies have reported differences in IL-6 production following activation of macrophages from Slc11a1 wt compared with mt mice, making this an interesting area for further research.
A number of studies have reported an association between enhanced IL-6 [and soluble (s)IL-6R] and colitis (reviewed in refs. [27] [28] [29] ). Previous consensus about the associated pathogenic mechanism has centered on the role of IL-6/STAT3 trans-signaling, i.e., signaling for STAT3 translocation to the nucleus by IL-6-sIL-6R complexes interacting with gp130 on membranes of CD4ϩ T cells, causing the induction of antiapoptotic genes, such as bcl-2 and bcl-xL, and leading to resistance of lamina propria T cells to apoptosis. The cycle of T cell accumulation, mediated by apoptosis resistance, leads to chronic inflammation, a process that can be blocked by anti-IL-6R antibodies. The increased IL-6 mRNA observed here in the acute phase of colitis in Slc1a1 wt compared with mt mice could contribute to the first round of this antiapoptotic cycle, leading to the dramatic differences that we observed between wt and mt mice following a second cycle of DSS treatment. In addition, recent attention [30] has focused on the demonstra- tion that IL-6 completely inhibits the generation of forkhead box P3 ϩ CD4 ϩ CD25 ϩ regulatory T cells induced by TGF-␤, instead acting with TGF-␤ to induce IFN-␥-generating Th17 cells. This subset of IL-17-producing Th17 cells is distinct from Th 1 or Th2 cells and has been shown to have a crucial role in the induction of autoimmune tissue injury. For example, a novel role for IL-6 in inducing rapid, spontaneous proliferation of naive CD8ϩ T cells, which is a crucial step in the differentiation of colitogenic CD8ϩ T cells and can be abrogated by anti-IL-6R treatment, has also been shown recently to operate through IL-17 [31] . The presence of a higher amount of IL-6 in the colons of Slc11a1 wt mice observed alongside enhanced IFN-␥, but not IL-12, is consistent with a role in Th17 cell rather than Th1 cell induction. Previous studies in mice have demonstrated [32] [33] [34] that Slc11a1 not only influences the immediate, proinflammatory macrophage activation response but also has long-term effects in determining Th1 versus Th2 bias in antigen-specific, T cell-mediated immune responses. This is the first suggestion that it may also have a role in Th17 induction.
Further work is required to determine how the effect of Slc11a1 in the colon relates to its primary function as a divalent cation transporter [35] localized to late endosomes/ lysosomes [4, 5] of macrophages and DC and whether the differences between wt and mt mice relate to macrophage interactions with commensal gut flora known [36] to drive the local expansion of CD4 T cells producing proinflammatory cytokines, including IL-17 (Th17 cells) in the colonic lamina propria. The issue of whether mature polymorphonuclear neu- trophils, which are known to express Slc11a1 [37] , contribute to differences between mt and wt mice in this model of colitis also needs to be addressed, although we known that neutrophils do not contribute to Slc11a1-mediated differences in early phases of S. typhimurium infection in mice [38] . In relation to macrophages and DC, a clear case can be made for a role for any one of the multiple Slc11a1-influenced, pleiotropic, proinflammatory and activation responses (reviewed in refs. [2, 3] ) in determining susceptibility to inflammatory and autoimmune diseases, and indeed, different pleiotropic effects might play different roles in each disease (reviewed in ref. [24] ). A direct role for divalent cation transport function in pathogenesis is also an attractive hypothesis. Patients suffering from rheumatoid arthritis, for example, show a statistically significant increase in iron deposits in the synovial membrane compared with osteoarthritis patients [39] , with an inverse correlation between the hemaglobin concentration and erythrocytes in the serum and the amount of iron in the synovial membrane. This could relate to the direct role Slc11a1 has in regulating cytoplasmic iron content and iron recycling [40, 41] . Similarly, iron deposition and iron-catalyzed oxidative damage are proposed [42, 43] as the underlying pathological basis to the development of cortical and subcortical gray matter hypointensities on T2-weighted magnetic resonance images in the brains of multiple sclerosis patients. In relation to the present research, recent epidemiological studies have shown that high iron content in drinking water is a risk factor for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease [44] . The relative risk of developing IBD increased by 21% (95% confidence interval: 9, 34) when the iron content in the drinking water increased by 0.1 mg/L. These observations prompt more interesting speculation that regulation of iron by SLC11A1 contributes directly to the disease phenotype in IBD. For now, the dramatic differences in acute colitis pathology that we have observed between Slc11a1 wt and mt mice, along with differences in IL-6 and IFN-␥ but not other proinflammatory cytokines in the colons following induction of acute ulcerative colitis, contribute to the growing evidence that IL-6 plays a crucial role early in the pathogenic process for this IBD.
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